scispace - formally typeset
Journal ArticleDOI

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Björn Dahlöf, +14 more
- 23 Mar 2002 - 
- Vol. 359, Iss: 9311, pp 995-1003
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
About: 
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.

read more

Citations
More filters
Journal ArticleDOI

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial

Sunil Bhandari, +8 more
- 30 Sep 2015 - 
TL;DR: Whether discontinuation of ACEi/ARBs can improve or stabilize renal function in patients with advanced progressive CKD will show whether this simple intervention can improve laboratory and clinical outcomes, including progression to end-stage renal disease, without causing an increase in cardiovascular events.
Journal ArticleDOI

Historical trends and milestones in hypertension research: a model of the process of translational research.

Theodore A. Kotchen
- 01 Oct 2011 - 
TL;DR: The purpose of this review is to summarize milestones in this ongoing translation process, a process that has had a considerable impact on patient care and reducing cardiovascular disease morbidity and mortality rates.
Journal ArticleDOI

Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.

Shosaku Nomura, +4 more
- 01 Apr 2004 - 
TL;DR: Combination therapy with a statin and angiotensin II receptor blocker might be valuable as anti-atherosclerotic therapy in patients with type 2 diabetes mellitus and nephropathy.
Journal ArticleDOI

Atherosclerosis and Oxidant Stress: The End of the Road for Antioxidant Vitamin Treatment?

Mika J. C. B. Thomson, +2 more
- 05 May 2007 - 
TL;DR: Increasing evidence suggests that more rigorous clinical trial designs are necessary to effectively divulge antioxidant utility and that a multifaceted antioxidant approach to atherosclerosis may yield the most clinical reward.
Journal ArticleDOI

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial

Mohapradeep Mohan, +15 more
- 01 Nov 2019 - 
TL;DR: Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials.
References
More filters
Journal ArticleDOI

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Salim Yusuf, +5 more
- 20 Jan 2000 - 
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Barry M. Brenner, +9 more
- 20 Sep 2001 - 
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

Lennart Hansson, +12 more
- 20 Feb 1999 - 
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI

An updated coronary risk profile. A statement for health professionals.

K M Anderson, +3 more
- 01 Jan 1991 - 
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

Bruce Neal, +2 more
- 09 Dec 2000 - 
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Salim Yusuf, +5 more
- 20 Jan 2000 - 

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Curt D. Furberg, +56 more
- 18 Dec 2002 - 

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Aram V. Chobanian, +10 more
- 21 May 2003 - 

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Barry M. Brenner, +9 more
- 20 Sep 2001 - 

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmond J Lewis, +9 more
- 20 Sep 2001 -